Welcome to our dedicated page for Assembly Bioscie news (Ticker: ASMB), a resource for investors and traders seeking the latest updates and insights on Assembly Bioscie stock.
Assembly Biosciences, Inc. (ASMB) is a clinical-stage biotechnology leader advancing innovative oral therapies for hepatitis B virus (HBV) and microbiome-related disorders. This news hub provides investors and researchers with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access authoritative reporting on ASMB's antiviral research programs and microbiome therapeutic platforms. Our curated news collection features press releases covering clinical trial progress, partnership announcements, and scientific presentations - all essential for informed analysis of the company's pipeline.
Key focus areas include updates on HBV core inhibitor candidates, microbiome strain development, and intellectual property advancements. Content is rigorously verified to ensure compliance with financial disclosure standards while maintaining scientific accuracy.
Bookmark this page for direct access to primary source materials and objective reporting on ASMB's pioneering work in oral antiviral therapies. Check regularly for the latest developments in this dynamic sector of precision medicine.
Assembly Biosciences (Nasdaq: ASMB) has shared Phase 1a clinical data for its HBV core inhibitor, ABI-4334, which shows promising efficacy against viral replication and cccDNA formation. The company is actively considering partnering options for its core inhibitor portfolio, aiming to advance the development of these therapies. In addition, Assembly Bio is prioritizing its antiviral pipeline, including ABI-5366 for high-recurrence genital herpes, with plans to enter clinical trials in the first half of 2024. The financial outlook remains strong, with an estimated cash runway extending into Q3 2024. CEO Jason Okazaki highlighted the need for longer-duration studies to validate the efficacy of core inhibitors. Overall, the results suggest a strong foundation for future development in HBV treatments.
Assembly Biosciences, Inc. (Nasdaq: ASMB) updated its progress on investigational hepatitis B virus (HBV) core inhibitors ABI-3733 and ABI-4334. The company is prioritizing ABI-4334 based on its superior potency and clinical profile while pausing ABI-3733 due to observed toxicity concerns. Preliminary data from ABI-3733’s Phase 1b trial showed significant viral suppression in patients. Financially, the company reported a net loss of $93.1 million for 2022, an improvement from $129.9 million in 2021. As of December 31, 2022, cash reserves were $91.6 million, projected to fund operations into mid-2024.
FAQ
What is the current stock price of Assembly Bioscie (ASMB)?
What is the market cap of Assembly Bioscie (ASMB)?
